Market Cap 145.75M
Revenue (ttm) 114.20M
Net Income (ttm) 120,000.00
EPS (ttm) N/A
PE Ratio 1.35
Forward PE 3.18
Profit Margin 0.11%
Debt to Equity Ratio -0.13
Volume 617,200
Avg Vol 869,374
Day's Range N/A - N/A
Shares Out 41.64M
Stochastic %K 89%
Beta 1.60
Analysts Sell
Price Target $12.33

Company Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGE...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 674 4400
Fax: 781 674 4200
Address:
3 Forbes Road, Lexington, United States
neversurrender2024
neversurrender2024 May. 31 at 3:54 AM
$AGEN garo chose france now france is burning...lol
0 · Reply
AAAGenBot
AAAGenBot May. 29 at 9:22 PM
$AGEN The Mink trial is now on the clinical trials - 90 patients - 4 sites including 3 US sites primary completion 6/27.
2 · Reply
manny11419
manny11419 May. 29 at 3:00 PM
$AGEN Replimmune sees a better FDA. https://www.cnbc.com/2026/05/29/replimune-resubmit-melanoma-drug-fda-makary.html
4 · Reply
Biotechguy21
Biotechguy21 May. 29 at 2:00 PM
$AGEN it must be painful to check the stock price every day and then know you were told what to do and yet you keep losing.
0 · Reply
BakerBrother
BakerBrother May. 29 at 12:58 PM
$AGEN where is the MSS-CRC phase 2 randomized trial results? Melanoma is not actionable.
2 · Reply
manny11419
manny11419 May. 29 at 12:35 PM
$AGEN The Agenus story going forward...is pretty straighforward. Its a binary play. If you believe the Mss Crc trial will eventually show an OS benefit, then the stock is cheap with significant return potential. CEOs always know much more than shareholders, as long as they're paying him in shares its a buy for me. While we all await, mgmt know how the first 10, 20, 30 patients are doing, while we wait for the full data package... Garo ain't going to sabotage a plane he's on.
2 · Reply
Biotechguy21
Biotechguy21 May. 29 at 10:22 AM
$AGEN 30 years of failing. CEO is the cfo. Board is in on the game. this is and always will be a pos stock. 👀👀💰💰💰🙏🙏🙏
0 · Reply
pedmac2000
pedmac2000 May. 29 at 4:03 AM
$AGEN this kind is stuff is how BP Here the FDA nod they promise future employment https://www.biospace.com/drug-development/lilly-just-bought-renowned-regulator-peter-marks-a-pipeline-to-play-with?utm_campaign=33719445-2026%20%7C%20Daily%20Social&utm_content=378818629&utm_medium=social&utm_source=linkedin&hss_channel=lcp-424124
4 · Reply
BakerBrother
BakerBrother May. 29 at 1:29 AM
$AGEN Public companies exist for their shareholders. Management is supposed to deliver financial returns and the Board is there to support this mission. Garo Armen has not delivered on any measure of shareholder return on any time frame.
1 · Reply
Biotechguy21
Biotechguy21 May. 28 at 8:55 PM
$AGEN well well you also said the RS was good for SHs. do you work for Garo? you sound like the others who will probably be investigated some day. 👀👀👀👀👀💰💰💰💰💰
0 · Reply
Latest News on AGEN
Agenus announces publication of Phase 1b BOT+BAL data

2026-05-15T20:23:26.000Z - 15 days ago

Agenus announces publication of Phase 1b BOT+BAL data


Agenus Proxy statement: Proxy filing

May 13, 2026, 8:00 AM EDT - 17 days ago

Agenus Proxy statement: Proxy filing


Agenus reports Q1 revenue $33.7M vs. $24.1M last year

2026-05-11T14:42:15.000Z - 19 days ago

Agenus reports Q1 revenue $33.7M vs. $24.1M last year


Agenus provides 2026 strategic priorities

2026-05-11T14:38:34.000Z - 19 days ago

Agenus provides 2026 strategic priorities


Agenus Earnings release: Q1 2026

May 11, 2026, 9:30 AM EDT - 19 days ago

Agenus Earnings release: Q1 2026


Agenus Quarterly report: Q1 2026

May 11, 2026, 9:30 AM EDT - 19 days ago

Agenus Quarterly report: Q1 2026


Agenus Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 weeks ago

Agenus Proxy statement: Proxy filing


Agenus Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 5 weeks ago

Agenus Proxy statement: Proxy filing


Agenus Transcript: AGM 2026

Mar 31, 2026, 4:30 PM EDT - 2 months ago

Agenus Transcript: AGM 2026


Agenus Annual report: Q4 2025

Mar 16, 2026, 9:30 AM EDT - 2 months ago

Agenus Annual report: Q4 2025


Agenus Earnings release: Q4 2025

Mar 16, 2026, 9:30 AM EDT - 2 months ago

Agenus Earnings release: Q4 2025


Agenus Transcript: Status update

Jan 28, 2026, 4:00 PM EST - 4 months ago

Agenus Transcript: Status update


Agenus to Host First 2026 Stakeholder Webcast

Jan 20, 2026, 6:24 PM EST - 4 months ago

Agenus to Host First 2026 Stakeholder Webcast


Agenus files to sell 1.32M shares of common stock or holders

2025-12-29T22:10:27.000Z - 5 months ago

Agenus files to sell 1.32M shares of common stock or holders


Agenus appoints Jose Iglesias as chief medical affairs officer

2025-11-18T14:36:16.000Z - 6 months ago

Agenus appoints Jose Iglesias as chief medical affairs officer


Agenus Quarterly report: Q3 2025

Nov 10, 2025, 9:30 AM EST - 7 months ago

Agenus Quarterly report: Q3 2025


Agenus Earnings release: Q3 2025

Nov 10, 2025, 9:30 AM EST - 7 months ago

Agenus Earnings release: Q3 2025


Agenus reports Q3 EPS $1.94, consensus $2.20

2025-11-10T13:05:24.000Z - 7 months ago

Agenus reports Q3 EPS $1.94, consensus $2.20


Agenus Transcript: Status Update

Oct 21, 2025, 4:00 PM EDT - 7 months ago

Agenus Transcript: Status Update


Agenus announces new data from its BOT/BAL at ESMO 2025

2025-10-17T12:10:28.000Z - 8 months ago

Agenus announces new data from its BOT/BAL at ESMO 2025


Agenus Slides: Corporate Presentation

Sep 8, 2025, 7:00 AM EDT - 9 months ago

Agenus Slides: Corporate Presentation


Agenus Transcript: Stakeholder Briefing

Aug 27, 2025, 4:00 PM EDT - 9 months ago

Agenus Transcript: Stakeholder Briefing


Agenus Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 10 months ago

Agenus Earnings Call Transcript: Q2 2025


Agenus Quarterly report: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 10 months ago

Agenus Quarterly report: Q2 2025


Agenus Earnings release: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 10 months ago

Agenus Earnings release: Q2 2025


Agenus Announces Virtual Annual Shareholders Meeting

Jun 10, 2025, 1:30 PM EDT - 1 year ago

Agenus Announces Virtual Annual Shareholders Meeting


Agenus Proxy statement: Proxy Filing

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Agenus Proxy statement: Proxy Filing


Agenus price target raised to $6 from $4 at Baird

2025-06-04T11:30:22.000Z - 1 year ago

Agenus price target raised to $6 from $4 at Baird


Agenus upgraded to Buy from Neutral at H.C. Wainwright

2025-06-04T10:10:31.000Z - 1 year ago

Agenus upgraded to Buy from Neutral at H.C. Wainwright


Agenus Transcript: Collaboration

Jun 3, 2025, 4:30 PM EDT - 1 year ago

Agenus Transcript: Collaboration


Agenus Press release: Collaboration

Jun 3, 2025, 4:30 PM EDT - 1 year ago

Agenus Press release: Collaboration


Agenus Earnings Call Transcript: Q1 2025

May 12, 2025, 8:30 AM EDT - 1 year ago

Agenus Earnings Call Transcript: Q1 2025


Agenus Quarterly report: Q1 2025

May 12, 2025, 8:30 AM EDT - 1 year ago

Agenus Quarterly report: Q1 2025


Agenus Earnings release: Q1 2025

May 12, 2025, 8:30 AM EDT - 1 year ago

Agenus Earnings release: Q1 2025


Agenus Registration statement: Registration Filing

May 12, 2025, 8:00 AM EDT - 1 year ago

Agenus Registration statement: Registration Filing


Agenus Proxy statement: Proxy Filing

May 5, 2025, 8:00 AM EDT - 1 year ago

Agenus Proxy statement: Proxy Filing


Agenus Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Agenus Proxy statement: Proxy Filing


Agenus Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Agenus Proxy statement: Proxy Filing


neversurrender2024
neversurrender2024 May. 31 at 3:54 AM
$AGEN garo chose france now france is burning...lol
0 · Reply
AAAGenBot
AAAGenBot May. 29 at 9:22 PM
$AGEN The Mink trial is now on the clinical trials - 90 patients - 4 sites including 3 US sites primary completion 6/27.
2 · Reply
manny11419
manny11419 May. 29 at 3:00 PM
$AGEN Replimmune sees a better FDA. https://www.cnbc.com/2026/05/29/replimune-resubmit-melanoma-drug-fda-makary.html
4 · Reply
Biotechguy21
Biotechguy21 May. 29 at 2:00 PM
$AGEN it must be painful to check the stock price every day and then know you were told what to do and yet you keep losing.
0 · Reply
BakerBrother
BakerBrother May. 29 at 12:58 PM
$AGEN where is the MSS-CRC phase 2 randomized trial results? Melanoma is not actionable.
2 · Reply
manny11419
manny11419 May. 29 at 12:35 PM
$AGEN The Agenus story going forward...is pretty straighforward. Its a binary play. If you believe the Mss Crc trial will eventually show an OS benefit, then the stock is cheap with significant return potential. CEOs always know much more than shareholders, as long as they're paying him in shares its a buy for me. While we all await, mgmt know how the first 10, 20, 30 patients are doing, while we wait for the full data package... Garo ain't going to sabotage a plane he's on.
2 · Reply
Biotechguy21
Biotechguy21 May. 29 at 10:22 AM
$AGEN 30 years of failing. CEO is the cfo. Board is in on the game. this is and always will be a pos stock. 👀👀💰💰💰🙏🙏🙏
0 · Reply
pedmac2000
pedmac2000 May. 29 at 4:03 AM
$AGEN this kind is stuff is how BP Here the FDA nod they promise future employment https://www.biospace.com/drug-development/lilly-just-bought-renowned-regulator-peter-marks-a-pipeline-to-play-with?utm_campaign=33719445-2026%20%7C%20Daily%20Social&utm_content=378818629&utm_medium=social&utm_source=linkedin&hss_channel=lcp-424124
4 · Reply
BakerBrother
BakerBrother May. 29 at 1:29 AM
$AGEN Public companies exist for their shareholders. Management is supposed to deliver financial returns and the Board is there to support this mission. Garo Armen has not delivered on any measure of shareholder return on any time frame.
1 · Reply
Biotechguy21
Biotechguy21 May. 28 at 8:55 PM
$AGEN well well you also said the RS was good for SHs. do you work for Garo? you sound like the others who will probably be investigated some day. 👀👀👀👀👀💰💰💰💰💰
0 · Reply
pedmac2000
pedmac2000 May. 28 at 5:48 PM
$AGEN https://www.linkedin.com/posts/ards-acutelunginjury-criticalcare-ugcPost-7465787908772405249-rlpG/?utm_source=share&utm_medium=member_ios&rcm=ACoAAAveofoBEIHGySHNXRoqoVBXQLJEYDfXVwM
0 · Reply
Scooter0732
Scooter0732 May. 28 at 5:30 PM
$AGEN After careful consideration, I voted in favor of all management’s proposals. Initially, I voted against option repricing. After further reflection, I changed my vote to support the repricing and here is why: The rank-and-file employees rely heavily on these options as their primary opportunity to participate in the company’s future, and preserving that incentive structure is very meaningful to them. Former employees are not eligible to participate, and approximately two-thirds of the repriced options are held by current non-management employees. As for allocated to management, I admittedly have reservations. That said, the repriced exercise prices are being reset at 50% above the current share price. It was ultimately a close decision for me. However, the prospect of leaving employees with effectively worthless options — and the resulting impact on morale and retention — led me to conclude that the organization would likely be stronger with the repricing proposal approved.
neversurrender2024
neversurrender2024 May. 28 at 1:50 PM
$AGEN what do they know......1 million more shorts shares..
0 · Reply
neversurrender2024
neversurrender2024 May. 28 at 1:40 PM
$AGEN when zachs pumps its a sell folks!
0 · Reply
pedmac2000
pedmac2000 May. 28 at 1:34 AM
$AGEN going all in I’m done bashing Garo !! This company is easily worth 5 times its value today Well maybe I’m adding a little This is like molasses
5 · Reply
weichsel1
weichsel1 May. 27 at 9:36 PM
$AGEN Remember results from last year: https://www.sec.gov/Archives/edgar/data/1098972/000095017025088502/agen-20250617.htm
2 · Reply
weichsel1
weichsel1 May. 27 at 9:35 PM
$AGEN Remember that last year - similar proposals to enrich management were DEFEATED in close votes - We can do it again: The Company’s stockholders did not approve Proposal 5. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 4,869,821 5,824,232 123,009 5,894,575 The Company’s stockholders did not approve Proposal 6. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 5,162,339 5,184,095 470,628 5,894,575 Please REPOST where appropriate. Vote against Proposals 3 and 4.
1 · Reply
weichsel1
weichsel1 May. 27 at 9:21 PM
$AGEN Now that Yahoo Message Boards are more limited - what OTHER message boards are heavily used regarding Agenus? Yahoo (with the account limitation)? Reddit seems dead. Anywhere else? Everyone please chime in !
1 · Reply
SuperGreenToday
SuperGreenToday May. 27 at 9:15 PM
$AGEN Share Price: $3.42 Contract Selected: Nov 20, 2026 $5 Calls Buy Zone: $0.13 – $0.16 Target Zone: $0.23 – $0.28 Potential Upside: 71% ROI Time to Expiration: 176 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
AAAGenBot
AAAGenBot May. 27 at 9:06 PM
$AGEN American Cancer Society updates guidelines for CRC 45 and above - https://pressroom.cancer.org/colorectal-cancer-screening-guideline-update-2026
0 · Reply
Biotechguy21
Biotechguy21 May. 27 at 8:03 PM
$AGEN this will always be a pos stock bc the ceo is the board and the cfo. you are screwed but if you want to learn how to make longest let me know 😂😂😂😂
0 · Reply
Biotechguy21
Biotechguy21 May. 27 at 8:02 PM
$AGEN you can’t win the vote bc you all don’t own enough shares. how dumb are some of you? 😂😂😂💰💰💰
0 · Reply